Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00005884
Other study ID # CDR0000067928
Secondary ID U01CA077158WCCC-
Status Completed
Phase Phase 3
First received
Last updated

Study information

Verified date September 2015
Source University of Wisconsin, Madison
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of eflornithine may be an effective way to prevent the recurrence of or further development of skin cancer.

PURPOSE: Randomized phase III trial to determine the effectiveness of eflornithine in preventing skin cancer in patients who have previously received treatment for early stage skin cancer.


Description:

OBJECTIVES: I. Compare the rate of new skin cancer in patients with previously treated stage 0, I, or II basal or squamous cell skin cancer treated with eflornithine (DFMO) vs placebo. II. Determine whether inhibition of TPA-induced ornithine decarboxylase activity serves as an intermediary marker for response to DFMO in these patients. III. Determine whether inhibition of skin polyamine levels serves as an intermediary marker for response to DFMO in these patients. IV. Assess the long term toxic effects of this treatment in these patients.

OUTLINE: This a randomized, double blind, placebo controlled, multicenter study. Patients receive oral placebo daily for the first 4 weeks. Patients who comply with taking 80-100% of placebo are randomized to one of two treatment arms. Arm I: Patients receive oral eflornithine (DFMO) daily. Arm II: Patients receive an oral placebo daily. Treatment continues for 3-5 years in the absence of unacceptable toxicity. Patients who develop skin cancer during study undergo surgical excision and continue treatment on the arm to which they were originally randomized. Patients are followed every 6 months through year 5.

PROJECTED ACCRUAL: A total of 334 patients (167 per arm) will be accrued for this study over 2 years.


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date
Est. primary completion date December 2000
Accepts healthy volunteers No
Gender All
Age group 21 Years to 120 Years
Eligibility DISEASE CHARACTERISTICS: Histologically proven previously treated stage 0, I, or II basal or squamous cell skin cancer

PATIENT CHARACTERISTICS: Age: 21 and over Performance status: ECOG 0-1 Life expectancy: Not specified Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 11.0 g/dL Hepatic: Bilirubin no greater than 2 mg/dL SGOT less than 3 times normal Renal: Creatinine less than 2.0 mg/dL Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No significant clinical hearing loss or use of hearing aid No family history of early retinal blindness or ornithine diaminotransferase deficiency

PRIOR CONCURRENT THERAPY: Biologic therapy: No prior bone marrow transplant No concurrent tamoxifen for cancer treatment or prophylaxis Chemotherapy: Greater than 4 weeks since prior chemotherapy No concurrent cytotoxic chemotherapy Endocrine therapy: Greater than 4 weeks since prior hormonal therapy for cancer No concurrent prednisone No concurrent hormonal therapy for cancer treatment or prophylaxis Radiotherapy: Greater than 4 weeks since prior radiotherapy Surgery: Greater than 4 weeks since prior major surgery No prior solid organ transplant Other: At least 4 weeks since prior topical medications (e.g., tretinoin, isotretinoin, psoralen ultraviolet light therapy, or fluorouracil) for skin cancer No concurrent antiseizure medication

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
eflornithine


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
University of Wisconsin, Madison National Cancer Institute (NCI)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00423397 - Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer Phase 1/Phase 2
Completed NCT00103246 - Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides Phase 1
Active, not recruiting NCT00391300 - Bioelectric Field Imaging in Diagnosing Melanoma and Other Skin Cancers in Patients With Skin Lesions Phase 1
Completed NCT00066872 - Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer Phase 3
Completed NCT00002963 - Photodynamic Therapy in Treating Patients With Skin Cancer Phase 2
Completed NCT00021294 - Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis Phase 2
Completed NCT00003611 - Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation N/A
Terminated NCT00663910 - Topical Aminolevulinic Acid in Patients With Nonmelanoma Skin Cancer Phase 0
Recruiting NCT00295906 - Computer-Based Continuing Education for Doctors in Examination and Counseling of Patients on Skin Cancer or Weight Control N/A
Completed NCT00025012 - Isotretinoin in Preventing Skin Cancer N/A
Completed NCT00021125 - Radiation Therapy in Treating Patients With Head and Neck Cancer Phase 3
Completed NCT00601640 - Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin Phase 2
Completed NCT00079300 - Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer Phase 1
Completed NCT00017485 - Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer Phase 1
Recruiting NCT00747903 - Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Skin Cancer Phase 2
Terminated NCT00899132 - Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer N/A
Completed NCT00099112 - Effect of Solar-Simulated Ultraviolet Radiation on Gene Expression in Unprotected and Sunscreen-Protected Skin of Healthy Adults With Fitzpatrick Skin Type II N/A
Completed NCT00644384 - Acitretin in Preventing Skin Cancer in Patients at High Risk for Skin Cancer N/A
Completed NCT00023621 - Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome Phase 2
Completed NCT00002975 - Photodynamic Therapy in Treating Patients With Skin Cancer Phase 2